奥沙二酮 | 27591-42-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 中文名称: 奥沙二酮
• 英文名称: 2-morpholin-4-ylmethyl-2-phenyl-indan-1,3-dione
• 英文别名: Oxazidione；2-(morpholin-4-ylmethyl)-2-phenylindene-1,3-dione
• CAS: 27591-42-0
• 化学式: C₂₀H₁₉NO₃
• 分子量: 321.376
• InChiKey: YYRYCTNXXHOENE-UHFFFAOYSA-N

物化性质

• 熔点：
  88° from cyclohexane
• 沸点：
  503.8±50.0 °C(Predicted)
• 密度：
  1.253±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  4

安全信息

• 海关编码：
  2934999090

文献信息

• [EN] INHIBITORS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE FOR TREATING CARDIOVASCULAR AND PULMONARY CONDITIONS<br/>[FR] INHIBITEURS DE LA GLUCOSE-6-PHOSPHATE DÉSHYDROGÉNASE PERMETTANT DE TRAITER DES AFFECTIONS CARDIOVASCULAIRES ET PULMONAIRES
  申请人：GUPTE SACHIN A

  公开号：WO2018093856A1

  公开（公告）日：2018-05-24

  The present disclosure provides for methods of treating or preventing a cardiovascular disorder and/or a related pulmonary disorder in a subject. In certain embodiments, the method comprises administering a therapeutically effective amount of an inhibitor of Glucose-6-phosphate dehydrogenase (G6PD), or a pharmaceutically acceptable salt, non-salt amorphous form, solvate, poly-morph, tautomer or prodrug thereof.

  本公开提供了用于治疗或预防受试者的心血管疾病和/或相关肺部疾病的方法。在某些实施例中，该方法包括向受试者投予治疗有效量的葡萄糖-6-磷酸脱氢酶（G6PD）抑制剂，或其药用可接受的盐、非盐非晶形态、溶剂合物、多形态、互变异构体或前药。
• Compositions and Methods for Cellular Imaging and Therapy
  申请人：Yang J. David

  公开号：US20070248537A1

  公开（公告）日：2007-10-25

  The present invention relates generally to the fields of chemistry and radionuclide imaging. More particularly, it concerns compositions, kits and methods for imaging and therapy involving N 4 compounds and derivatives.

  本发明一般涉及化学和放射性核素成像领域。更具体地，涉及涉及N4化合物及其衍生物的成分、试剂盒和成像和治疗方法。
• [EN] (S) - ENOXIMONE SULFOXIDE AND ITS USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES<br/>[FR] SULFOXYDE DE (S)-ENOXIMONE ET SON UTILISATION DANS LE TRAITEMENT DE MALADIES MEDIEES PAR PDE-III
  申请人：MYOGEN INC

  公开号：WO2005092332A1

  公开（公告）日：2005-10-06

  The present invention provides the (S)-(-) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (S)-(-) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial.

  本发明提供了（S）-（-）恩奥西莫酮亚砜对映体，以及纯化的（S）-（-）亚砜对映体的药物配方。还提供了在其中抑制PDE-III可能有益的治疗疾病的方法。
• [EN] (R)-ENOXIMONE SULFOXIDE AND ITS USE IN THE TREATMENT OF PDE-III MEDIATED DISEASES<br/>[FR] (R)-ENOXIMONE SULFOXYDE ET SON UTILISATION DANS LE TRAITEMENT DE MALADIES INDUITES PAR PDE-III
  申请人：MYOGEN INC

  公开号：WO2005092333A1

  公开（公告）日：2005-10-06

  The present invention provides the (R)-(+) enoximone sulfoxide enantiomer, as well as pharmaceutical formulations of the purified (R)-(+) sulfoxide enantiomer. Also provided are methods of treating diseases in which inhibition of PDE-III may be beneficial.

  本发明提供了（R）-（+）羟亚胺磺酰氧化物对映体，以及纯化的（R）-（+）磺酰氧化物对映体的药物配方。还提供了在其中抑制PDE-III可能有益的治疗疾病的方法。
• [EN] METHODS AND COMPOSITIONS INVOLVING (S)-BUCINDOLOL<br/>[FR] MÉTHODES ET COMPOSITIONS METTANT EN JEU DU (S)-BUCINDOLOL
  申请人：ARCA DISCOVERY INC

  公开号：WO2010014263A1

  公开（公告）日：2010-02-04

  Disclosed is bucindolol substantially free of its R-stereoisomer. Also disclosed are pharmaceutical compositions that include bucindolol substantially free of its R-stereoisomer or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier. Also disclosed are methods of treating a patient that involve administering to the patient a therapeutically effective amount of a composition of the present invention. Formula (I).

  本发明公开了几乎不含其R-立体异构体的布辛多洛。还公开了包括几乎不含其R-立体异构体或其药学上可接受的盐以及药学上可接受的载体的布辛多洛制剂。还公开了治疗患者的方法，该方法涉及向患者投与本发明组合物的治疗有效量。公式（I）。